US ruling upheld, generics firms must pay legal fees to Takeda
This article was originally published in Scrip
Executive Summary
The US Court of Appeals for the Federal Circuit has affirmed the 2006 ruling of a lower court which grantedTakeda's motion for an award of attorneys' fees against Alphapharm and MylanLaboratories in connection with patent infringement litigation relating to the antidiabetic Actos (pioglitazone).